These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 12047023)

  • 1. The schizophrenia PORT pharmacological treatment recommendations: conformance and implications for symptoms and functional outcome.
    Buchanan RW; Kreyenbuhl J; Zito JM; Lehman A
    Schizophr Bull; 2002; 28(1):63-73. PubMed ID: 12047023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship of the use of adjunctive pharmacological agents to symptoms and level of function in schizophrenia.
    Buchanan RW; Kreyenbuhl J; Zito JM; Lehman A
    Am J Psychiatry; 2002 Jun; 159(6):1035-43. PubMed ID: 12042194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder.
    Elie D; Poirier M; Chianetta J; Durand M; Grégoire C; Grignon S
    J Psychopharmacol; 2010 Jul; 24(7):1037-44. PubMed ID: 19164494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of lamotrigine to clozapine in inpatients with chronic psychosis.
    Heck AH; de Groot IW; van Harten PN
    J Clin Psychiatry; 2005 Oct; 66(10):1333. PubMed ID: 16259551
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study.
    Mayoral-van Son J; de la Foz VO; Martinez-Garcia O; Moreno T; Parrilla-Escobar M; Valdizan EM; Crespo-Facorro B
    J Clin Psychiatry; 2016 Apr; 77(4):492-500. PubMed ID: 26759992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effects of Psychoeducation on Long-term Inpatients with Schizophrenia and Schizoaffective Disorder.
    Yanagida N; Uchino T; Uchimura N
    Kurume Med J; 2017 May; 63(3.4):61-67. PubMed ID: 28381728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial.
    Lerner V; Miodownik C; Gibel A; Sirota P; Bush I; Elliot H; Benatov R; Ritsner MS
    J Clin Psychiatry; 2013 Dec; 74(12):1224-32. PubMed ID: 24434091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-acting injectable risperidone in treatment refractory patients: a 14-week open-label pilot study.
    Procyshyn RM; Barr AM; Flynn S; Schenk C; Ganesan S; Honer WG
    Schizophr Res; 2010 Nov; 123(2-3):273-5. PubMed ID: 20688481
    [No Abstract]   [Full Text] [Related]  

  • 9. [Atypical antipsychotic agents in the adolescent: what implications for the future?].
    Cohen D
    Encephale; 2011 Sep; 37(4 Suppl 4):H15-7. PubMed ID: 22108183
    [No Abstract]   [Full Text] [Related]  

  • 10. Compliance and schizophrenia: the predictive potential of insight into illness, symptoms, and side effects.
    Kao YC; Liu YP
    Compr Psychiatry; 2010; 51(6):557-65. PubMed ID: 20965300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antipsychotic efficacy of fluperlapine. An open multicenter trial.
    Woggon B; Angst J; Bartels M; Heinrich K; Hippius H; Koukkou M; Krebs E; Küfferle B; Müller-Oerlinghausen B; Pöldinger W
    Neuropsychobiology; 1984; 11(2):116-20. PubMed ID: 6148712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder.
    Krakowski MI; Czobor P; Citrome L; Bark N; Cooper TB
    Arch Gen Psychiatry; 2006 Jun; 63(6):622-9. PubMed ID: 16754835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
    Wang X; Savage R; Borisov A; Rosenberg J; Woolwine B; Tucker M; May R; Feldman J; Nemeroff CB; Miller AH
    J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Partial response to antipsychotic treatment: the patient with enduring symptoms.
    Emsley RA
    J Clin Psychiatry; 1999; 60 Suppl 23():10-3. PubMed ID: 10625194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remission in prognosis of functional outcome: a new dimension in the treatment of patients with psychotic disorders.
    Helldin L; Kane JM; Karilampi U; Norlander T; Archer T
    Schizophr Res; 2007 Jul; 93(1-3):160-8. PubMed ID: 17395430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spirituality and religion in outpatients with schizophrenia: a multi-site comparative study of Switzerland, Canada, and the United States.
    Mohr S; Borras L; Nolan J; Gillieron C; Brandt PY; Eytan A; Leclerc C; Perroud N; Whetten K; Pieper C; Koenig HG; Huguelet P
    Int J Psychiatry Med; 2012; 44(1):29-52. PubMed ID: 23356092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective 1-5 year outcome study in first-admitted and readmitted schizophrenic patients; relationship to heredity, premorbid adjustment, duration of disease and education level at index admission and neuroleptic treatment.
    Wieselgren IM; Lindstrom LH
    Acta Psychiatr Scand; 1996 Jan; 93(1):9-19. PubMed ID: 8919324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of factors influencing medication compliance in inpatient treatment of psychotic disorders.
    Janssen B; Gaebel W; Haerter M; Komaharadi F; Lindel B; Weinmann S
    Psychopharmacology (Berl); 2006 Aug; 187(2):229-36. PubMed ID: 16710714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy.
    Clark RE; Bartels SJ; Mellman TA; Peacock WJ
    Schizophr Bull; 2002; 28(1):75-84. PubMed ID: 12047024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable.
    Gharabawi G; Bossie C; Turkoz I; Kujawa M; Mahmoud R; Simpson G
    J Nerv Ment Dis; 2007 Dec; 195(12):976-82. PubMed ID: 18091190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.